Compare VVOS & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VVOS | LIXT |
|---|---|---|
| Founded | 2016 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4M | 20.5M |
| IPO Year | 2020 | N/A |
| Metric | VVOS | LIXT |
|---|---|---|
| Price | $2.05 | $4.06 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $6.75 | N/A |
| AVG Volume (30 Days) | ★ 116.0K | 85.0K |
| Earning Date | 11-19-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,317,000.00 | N/A |
| Revenue This Year | $19.45 | N/A |
| Revenue Next Year | $70.80 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.76 | N/A |
| 52 Week Low | $1.98 | $0.64 |
| 52 Week High | $7.95 | $6.26 |
| Indicator | VVOS | LIXT |
|---|---|---|
| Relative Strength Index (RSI) | 33.84 | 42.81 |
| Support Level | $2.03 | $3.53 |
| Resistance Level | $2.33 | $4.80 |
| Average True Range (ATR) | 0.16 | 0.45 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 4.35 | 35.07 |
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.